{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:35:14Z","timestamp":1768977314790,"version":"3.49.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T00:00:00Z","timestamp":1187136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p><jats:list list-type=\"explicit-label\"><jats:list-item><jats:p>The aim of the present study was to determine whether inhibition of dipeptidyl peptidase IV (DPP IV) elevates arterial blood pressure and whether any such effect is dependent on genetic background, the sympathetic nervous system and Y<jats:sub>1<\/jats:sub>receptors. The rationale behind this study was that: (i) neuropeptide (NP) Y<jats:sub>1\u201336<\/jats:sub>and peptide YY<jats:sub>1\u201336<\/jats:sub>(PYY<jats:sub>1\u201336<\/jats:sub>) are endogenous Y<jats:sub>1<\/jats:sub>receptor agonists and are metabolised by DPP IV to NPY<jats:sub>3\u201336<\/jats:sub>and PYY<jats:sub>3\u201336<\/jats:sub>, which are not Y<jats:sub>1<\/jats:sub>but rather selective Y<jats:sub>2<\/jats:sub>receptor agonists; (ii) Y<jats:sub>1<\/jats:sub>receptors mediate vasoconstriction, whereas Y<jats:sub>2<\/jats:sub>receptors have little effect on vascular tone; (iii) vaso<jats:roman>\u2010<\/jats:roman>constrictor effect of the Y<jats:sub>1<\/jats:sub>receptor is enhanced in spontaneously hypertensive rats (SHR) compared with normotenisve Wistar\u2010Kyoto (WKY) rats; and (iv) NPY<jats:sub>1\u201336<\/jats:sub>is released from sympathetic nerve terminals.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>We examined the effects of acute administration of 3\u2010<jats:italic>N<\/jats:italic>\u2010[(2S,3S)\u20102\u2010amino\u20103\u2010methylpentanoyl]\u20101,3\u2010thiazolidine (P32\/98; a DPP IV inhibitor) on arterial blood pressure in anaesthetized adult SHR and WKY rats in the absence and presence of either captopril, hydralazine or chlorisondamine to lower basal mean arterial blood pressure (MABP) by different mechanisms (inhibition of angiotensin\u2010converting enzyme, direct vasodilation and ganglionic blockade, respectively).<\/jats:p><\/jats:list-item><jats:list-item><jats:p>In na\u00efve SHR with severely elevated basal blood pressures (MABP\u00a0=\u00a0176\u00a0\u00b1\u00a03\u00a0mmHg;<jats:italic>n<\/jats:italic>\u00a0=\u00a04), i.v. boluses (1, 3 and 10\u00a0mg\/kg) of P32\/98 did not affect blood pressure.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>When basal blood pressure was reduced by pretreatment of SHR with either captopril (30\u00a0mg\/kg, i.v.; MABP\u00a0=\u00a0116\u00a0\u00b1 3\u00a0mmHg;<jats:italic>n<\/jats:italic>\u00a0=\u00a09) or hydralazine (5\u00a0mg\/kg, i.p.; MABP\u00a0=\u00a084\u00a0\u00b1 3\u00a0mmHg;<jats:italic>n<\/jats:italic>\u00a0=\u00a07), P32\/98 (1, 3 and 10\u00a0mg\/kg) caused significant dose\u2010related increases in arterial blood pressure (4\u00a0\u00b1\u00a02, 10\u00a0\u00b1\u00a02 and 12\u00a0\u00b1\u00a03\u00a0mmHg in the captopril\u2010pretreated group, respectively (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01); 5\u00a0\u00b1\u00a02, 8\u00a0\u00b1\u00a03 and 11\u00a0\u00b1\u00a04\u00a0mmHg in the hydralazine\u2010pretreated group, respectively (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01)).<\/jats:p><\/jats:list-item><jats:list-item><jats:p>The increases in arterial blood pressure induced by P32\/98 in captopril\u2010 or hydralazine\u2010pretreated SHR were entirely blocked by pretreatment with the selective Y<jats:sub>1<\/jats:sub>receptor antagonist<jats:italic>N<\/jats:italic>2\u2010(diphenylacetyl)\u2010<jats:italic>N<\/jats:italic>\u2010[(4\u2010hydroxyphenyl)methyl]\u2010<jats:sc>d<\/jats:sc>\u2010arginine amide (BIBP\u00a03226; 6\u00a0mg\/kg per h).<\/jats:p><\/jats:list-item><jats:list-item><jats:p>When basal blood pressure was reduced in SHR by pretreatment with chlorisondamine (10\u00a0mg\/kg, s.c.; MABP\u00a0= 108\u00a0\u00b1\u00a04\u00a0mmHg;<jats:italic>n<\/jats:italic>\u00a0=\u00a07), inhibition of DPP IV with P32\/98 did not affect arterial blood pressure. Basal heart rate in chlorisondamine\u2010treated SHR was significantly reduced compared with na\u00efve SHR, captopril\u2010pretreated SHR and hydralazine\u2010pretreated SHR, indicating effectiveness of ganglionic blockade.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>Unlike the results in genetically hypertensive animals, in normotensive WKY rats pretreated with captopril (30\u00a0mg\/kg, i.v.; MABP\u00a0=\u00a081\u00a0\u00b1\u00a04\u00a0mmHg;<jats:italic>n<\/jats:italic>\u00a0=\u00a06), or hydralazine (5\u00a0mg\/kg, i.p.; MABP\u00a0=\u00a063\u00a0\u00b1\u00a04\u00a0mmHg;<jats:italic>n<\/jats:italic>\u00a0=\u00a04) or chlorisondamine (10\u00a0mg\/kg, s.c.; MABP\u00a0=\u00a063\u00a0\u00b1\u00a04\u00a0mmHg;<jats:italic>n<\/jats:italic>\u00a0=\u00a05), P32\/98 did not affect arterial blood pressure.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>We conclude that, in genetically susceptible animals, inhibition of DPP IV increases arterial blood pressure via Y<jats:sub>1<\/jats:sub>receptors when elevated blood pressure is reduced with antihypertensive drugs provided that the sympathetic nervous system is functional. The results suggest vigilance because DPP IV inhibitors are used more widely in hypertensive patients treated with antihypertensive drugs.<\/jats:p><\/jats:list-item><\/jats:list><\/jats:p>","DOI":"10.1111\/j.1440-1681.2007.04737.x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T04:59:26Z","timestamp":1187326766000},"page":"29-34","source":"Crossref","is-referenced-by-count":65,"title":["EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSURE"],"prefix":"10.1111","volume":"35","author":[{"given":"Edwin K","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H","family":"Dubinion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaichuan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2004.06.001"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2005.05.010"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867053507298"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:29:1:109"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/153537020322800301"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0031-6997(24)01352-8","article-title":"XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors","volume":"50","author":"Michel MC","year":"1998","journal-title":"Pharmacol. Rev"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000197033.54756.83"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.69031048.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.07.008"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00168634"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000159011"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1515\/bchm3.1991.372.1.305"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.47.8.1253"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.943"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2003.08.028"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00372-X"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007726626924"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00186.2004"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00209.2004"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071889"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2007.04737.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2007.04737.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:16:21Z","timestamp":1737375381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2007.04737.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1440-1681.2007.04737.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2007.04737.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}